Genfleet Therapeutics (2595 HK)

Analysis

Health Care • China

Genfleet Therapeutics is a biopharmaceutical company focused on developing innovative treatments for oncology, including various solid tumors, and autoimmune and inflammatory diseases. The company's pipeline includes products like GFH925 (fulzerasib) for advanced non-small cell lung cancer and GFH375, a KRAS G12C inhibitor. Genfleet Therapeutics was incorporated in 2017 and is headquartered in Shanghai, China.

Refresh

Company Presentation • 27 Oct 2025 17:00

Study update presentation

Company Presentation • 10 Dec 2025 17:00

Investor Day presentation

Company Presentation • 02 Jun 2026 16:00

Study result presentation

Company Presentation • 14 Sep 2026 16:00

2026 World Conference on Lung Cancer presentation

Company Presentation • 15 Sep 2026 16:00

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00